FDAnews
www.fdanews.com/articles/138892-map-pharmaceuticals-announces-fda-acceptance-for-filing-of-nda-for-levadex

MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex

August 2, 2011
MAP Pharmaceuticals announced its New Drug Application for Levadex orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration.
MarketWatch